Skip to content

Elective Adhesiolysis vs. a Wait-and-see Policy to Prevent Recurrences After Conservative Treatment of Adhesive Small Bowel Obstruction

Elective Adhesiolysis vs. a Wait-and-see Policy to Prevent Recurrences After Conservative Treatment of Adhesive Small Bowel Obstruction

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06777446
Acronym
AWARE
Enrollment
380
Registered
2025-01-15
Start date
2025-02-28
Completion date
2034-02-28
Last updated
2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive Small Bowel Obstruction

Keywords

Tissue adhesions, Adhesiolysis, Surgery

Brief summary

Rationale: Adhesive small bowel obstruction (aSBO) is a frequent surgical emergency, associated with 3-8% hospital mortality and a high risk of recurrence (20% at two years of follow-up). ASBO can be treated conservatively or by emergency surgery. In the absence of bowel ischemia or strangulation, conservative treatment is often preferred, to avoid the excess morbidity and mortality from emergency surgery. Recent epidemiological studies, however, demonstrate a considerable higher recurrence risk of aSBO after conservative treatment that is associated with hospital readmissions and lower survival. Elective adhesiolysis following successful conservative treatment might reduce these long-term risks whilst avoiding the high complication rate of emergency surgery. Objective: The investigators aim to assess the efficacy of elective adhesiolysis following conservative treatment for aSBO as compared to the current state of the art (wait-and-see policy) to prevent long-term recurrence of aSBO. Further the investigators will evaluate quality of life, healthcare and societal costs. Study design: Multicenter open-label randomized controlled trial, including 380 patients. Study population: Adult patients who recovered from aSBO by conservative treatment. Patients that are inoperable for medical, anaesthesiological or surgical reasons are excluded. Intervention (if applicable): The intervention of investigation is elective adhesiolysis. Adhesiolysis is an abdominal procedure in which all adhesions are cut, and adhesion prevention applied to reduce the risk of adhesion reformation. The intervention is compared to wait-and-see policy (the current standard treatment) Main study parameters/endpoints: Primary outcome is recurrence, defined as readmission for obstructive systems with aetiology of adhesions confirmed by CT. The investigators hypothesize a 50% reduction in recurrence in the intervention arm. Secondary outcomes are morbidity from surgery, health-related quality of life (EQ5D), healthcare costs and societal costs (iMCQ and iPCQ) Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients in the intervention group are exposed to abdominal surgery, which is associated with a moderate risk of minor complications such as wound infection and haemorrhage, and a small risk of severe complications such as iatrogenic bowel injury. According to our hypothesis, a potential benefit is the reduction in the risk of recurrences. Recurrence of aSBO is associated with a risk of readmissions, reinterventions, and also increased long-term mortality.

Interventions

PROCEDUREElective Adhesionlysis

See descriptions in study arms

At the end of adhesiolysis a barrier will be placed. The adhesion barrier to be used in laparoscopic adhesiolysis is Icodextrin 4% (Adepttm).

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
KCE Belgian Healthcare Knowledge Centre
CollaboratorUNKNOWN
Baxter Healthcare Corporation
CollaboratorINDUSTRY
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multicenter open-label randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18 years and older who have recently recovered from aSBO by small bowel obstruction managed by conservative treatment. * Patients who have previously been operated (high a prior risk of adhesions) are required to have no signs of other causes of bowel obstruction on imaging studies (CT-scan). * Patients with no previous operation in history (low a prior risk of adhesions) are required to have typical signs for aSBO on imaging studies (abrupt change of bowel calibre, closed loop, or signs of torsion on vessels in the mesentery on CT-scan).

Exclusion criteria

* Patient who are unfit for reoperation for surgical, anesthesiological or medical reasons as determined by multidisciplinary team assessment or pre-operative screening * Patients with active malignancy, reducing life expectancy * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
recurrence of ASBO at 2-years of follow-up2 yearsRecurrence is defined as a readmission for symptoms of small bowel obstruction, including lower abdominal pain, bloating and nausea with or without vomiting. In addition imaging by CT-scan should not show indications of other causes of bowel obstruction (such as an incarcerated abdominal wall hernia or tumour), which is over 90% accurate for the diagnosis of ASBO.

Secondary

MeasureTime frameDescription
Societal costs2 yearsmeasured by modified iMCQ
Recurrence at 5 year5 years(identified by record linking\[BE\] or general practitioner data\[NL\])
Recurrences needing surgery2 years and 5 yearsASBO recurrence requiring emergency surgery
Healthcare costs2 yearsmeasured by modified iMCQ
Health related quality of life2 years\- Health-related quality of life measured by EQ5D
Gastro-intestinal related quality of life2 years\- Gastro-intestinal related quality of life measured by GIQLI
Cost-effectiveness2 years and 5 yearsincremental cost-effectiveness ratio, i.e. cost per QALY
Morbidity from elective adhesiolysis90 daysComposite of: * Serious adverse events and complications, graded by Clavien-Dindo score. * Intra-operative events (i.e. bowel injury), graded by ClassIntra® * ICU admission * Reinterventions within 90 days

Countries

Belgium, Netherlands

Contacts

Primary ContactRichard PG ten Broek, MD, PhD
richard.tenbroek@radboudumc.nl+31243611111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026